key: cord-0851375-b2vjrskm
authors: Zhao, Juanjuan; Liao, Xuejiao; Wang, Haiyan; Wei, Lanlan; Xing, Mingzhao; Liu, Lei; Zhang, Zheng
title: Early virus clearance and delayed antibody response in a case of COVID-19 with a history of co-infection with HIV-1 and HCV
date: 2020-04-09
journal: Clin Infect Dis
DOI: 10.1093/cid/ciaa408
sha: e1bad056f83cd65f8a99b4bc5ee1d6e229c66c4f
doc_id: 851375
cord_uid: b2vjrskm

The effect of host immune status on SARS-CoV-2 infection remains unknown. Here, we report the first case of COVID-19 with HIV-1 and HCV co-infection, who showed a persistently negative SARS-CoV-2 RNA test, but delayed antibody response in the plasma. This case highlights the influence of HIV-1-induced immune dysfunction on the early SARS-CoV-2 clearance.

M a n u s c r i p t

In late December, 2019, the outbreak of coronavirus disease 2019 (COVID-19) caused by a novel coronavirus (named SARS-CoV-2) started in Wuhan, China, which has quickly spread to many countries in the world 1 . Clinical manifestations of COVID-19 have been shown to vary widely, from asymptomatic clinical presentation to acute respiratory distress syndrome (ARDS) [2] [3] [4] . It remains unknown what host factors may affect the clinical presentation of COVID-19. Our recent studies indicated that monocyte-derived FCN1+ macrophages in bronchoalveolar lavage fluid (BALF) overwhelmed in the severely damaged lungs, while the formation of tissue resident with highly expanded clonal CD8+ T cells in mildly symptomatic patients suggested a robust adaptive immune response associated with better control of COVID-19 5 . Moreover, a higher titer of antibody in the plasma was independently associated with disease severity in patients with COVID-19 6 . These data suggest that the host immune status, to some extent, may affect the outcomes of SARS-CoV-2 infection. However, there is lack of direct evidence for immune influence on the acute infection of SARS-CoV-2. Here, we report a unique case of COVID-19 with preexisting immune dysfunction from previous coinfection of HIV and HCV, who showed persistently negative SARS-CoV-2 RNA test but delayed antibody response in the plasma. COI, which were significantly lower and higher, respectively, than those in patients with COVID-19 who had recovered from the illness. At this time, his SARS-CoV-2 RNA A c c e p t e d M a n u s c r i p t test was still negative from nasopharyngeal and anal swabs. Also, RNAs of influenza A and B and respiratory syncytial virus were all negative. One week later, 49 days from the onset of illness, his plasma total Ab rose to 523.8 COI while IgM remained at similar levels with 54 COI (Table 1) .

Retrospectively, the patient had been previously co-infected with HIV-1 and HCV through homosexual transmission. After he was diagnosed with co-infection of HIV-1 and HCV in 2016 when his CD4 T cell count was 84 cells/µl, he had been taking lamivudine, tenofovir and efavirenz until today. In 2017, he took antiviral agents (DAA) against HCV for 3 months by himself, and HCV became persistently negative.

During the past two years, his CD4 T cell counts have been fluctuating between 250-300 cells/µl. On March 2, 2020, his CD4 and CD8 T cell counts in peripheral blood were 216 and 584, respectively. On March 9, 2020 his CD4 and CD8 T cell counts were slightly increased and plasma HIV-1 and HCV were both tested negative (Table   1 ). Since the onset of COVID illness in this patient, his close contact partner, an HIV-1-infected person currently taking lopinavir and ritonavir, was tested to be negative for SARS-CoV-2. Notably, the SARS-CoV-2-specific total antibody titer was low and IgM was high even after 42 days of illness, which was significantly different from antibody levels in other patients who have recovered from COVID-19 at the similar time points of the illness. Importantly, the total Ab level was largely increased and IgM remained at the peak level one week later, suggesting that the antibody responses against SARS-CoV-2 in this HIV-1-infected case were delayed. It is possible that there was early incomplete clearance of the virus that induced the subsequently delayed antibody response. Future studies are needed to address the mechanism underlying this delayed antibody response to SARS-CoV-2 with a history of coinfection of HIV-1 infection and HCV, even with the latter being cleared in this case.

In summary, we report for the first time a case of COVID-19 with a history of co-infection A c c e p t e d M a n u s c r i p t

A Novel Coronavirus from Patients with Pneumonia in China

Clinical features of patients infected with 2019 novel coronavirus in Wuhan

Asymptomatic cases in a family cluster with SARS-CoV-2 infection

Clinical characteristics of 138 hospitalized patients with 2019 novel coronavirus-infected pneumonia in Wuhan

The landscape of lung bronchoalveolar immune cells in COVID-19 revealed by single-cell RNA sequencing

The level of plasma C-reactive protein is closely related to the liver injury in patients with COVID-19

Compounds with therapeutic potential against novel respiratory

Sustained IFN-I stimulation impairs MAIT cell responses to bacteria by inducing IL-10 during chronic HIV-1 infection

We declare no competing interests.

A c c e p t e d M a n u s c r i p t A c c e p t e d M a n u s c r i p t e, The median and range of plasma total antibody titers in 12 patients who recovered from COVID-19 with similar illness dates.